Influenza: A seasonal disease
Influenza or ‘flu’ is a common viral disease of the upper respiratory tract in humans (in birds it is an infection of the gut). There are three types of influenza virus: influenza A, B and C. However, a fourth type, influenza D, has recently been discovered as a veterinary infection, particularly of cows. Major outbreaks of influenza are associated with influenza virus type A or B. Influenza C is common but seldom causes disease.

Influenza A is commonly associated with human disease. Each year, many countries, including the UK, experience seasonal influenza epidemics that affect hundreds of thousands of people. In addition, global influenza pandemics have been recorded throughout history and they seem to occur every 10 to 40 years. Between 1918 and 1919 flu is thought to have killed over 50 million people (6 times as many as died as a consequence of the first-world war). It was caused by an unusually pathogenic strain of influenza A virus.

What causes flu?
The influenza virus particle – virion – is usually spherical, but sometimes filamentous, in shape and carries its genetic material on eight pieces of single stranded RNA known as segments. Each segment carries genes that encode proteins that the virus needs in order to replicate inside the infected host cell. The genome is protected by a membrane envelope. Protruding from the virus membrane are hundreds of copies of two different varieties of viral glycoprotein spikes. Approximately 80% of the spikes are haemagglutinin (HA) and the remaining 20% are neuraminidase (NA). The HA and NA surface proteins are involved in viral attachment and entry to host cells as well as the release of new virions. They are also the main part of the virus recognised by our immune system as foreign, and most of the antibodies we make after infection are against these antigens.
Transmission
The flu virus is extremely contagious and is transmitted from person to person by droplets expelled when sneezing, coughing and even breathing. It can also be transmitted by direct contact, for example, by touching virus-contaminated surfaces such as door handles and then touching your eyes or nose. Good hygiene practices, such as correct handwashing, can help to prevent infection.

Infection and replication
Influenza viruses infect epithelial cells in the upper respiratory tract (nose and throat). If the infection is severe the virus can eventually reach the lungs and cause pneumonia. The respiratory tract’s first line of defence is a protective layer of mucus. The viral NA protein can cut through this enabling the virus particle to reach the epithelial cell surface. The virus then uses its HA protein to attach to a receptor on the host cell’s plasma membrane and is taken into the host cell by endocytosis. The ribonucleoprotein
The terms ‘cold’ and ‘flu’ are often used interchangeably but they are in fact distinct diseases caused by very different viruses. A cold is caused by several groups of viruses; the most common is rhinovirus and usually lasts between 2 and 4 days. Symptoms include runny nose, sneezing and mild fatigue.

Flu is much more serious than a cold. Symptoms may last for a few weeks and the illness can be much more debilitating. If in doubt, remember the £50 test: if a £50 note is pinned to your front door and you are incapable of dragging yourself out of your sick bed to collect it ... you have flu. If the thought of free money puts a spring in your step ... it’s just a cold!
Factfile: Influenza

Oseltamivir (Tamiflu®) is a medication that attacks the virus by inhibiting the NA enzyme and therefore preventing the virus from infecting cells. Antibiotics are not used to treat influenza because they specifically work by inhibiting bacterial cell wall production or protein synthesis and metabolism and have no effect on viruses. They can be used to treat secondary bacterial infections.

The host cells' own ribosomes are hijacked to make proteins from the viral mRNAs. New copies of the RNA genome are shuttled out of the nucleus and up to the plasma membrane, where they combine with the newly made viral proteins and bud out of the cell’s plasma membrane, acquiring their envelope in the process. Finally, using the NA protein to cut themselves away from the infected cells, the new virions move away to infect other cells.

The host cells are damaged when they become infected by the virus. The patient’s immune system responds by releasing chemicals called cytokines which stimulate leukocytes (white blood cells) to travel to the site of infection and fight the virus. Most of the symptoms are in fact caused by the body’s immune response. These include:

- high fever
- chills
- severe fatigue
- headaches
- muscular aches and pains
- non-productive cough
- sore throat

When the NA protein of influenza breaks down the mucus lining the epithelial cells, this also leaves the cells more susceptible to infection by other pathogens, such as bacteria like Staphylococcus aureus and Haemophilus influenzae.

Treatment

Most people recover from flu within 1–2 weeks but more serious illness, and even death, can result from secondary infections e.g. bacterial pneumonia. This is more likely in infants, the elderly, people who are immunocompromised and those with chronic lung disease such as emphysema.

There are two ways of tackling the disease: treating the symptoms and attacking the virus. The symptoms can be alleviated with drugs to reduce fever and pain such as paracetamol. Antiviral drugs can be effective against influenza but must be administered within the first 2 days of symptoms appearing. Drugs such as oseltamivir (Tamiflu®) attack the virus by inhibiting the NA enzyme and therefore preventing the virus from infecting cells.

Antibiotics are not used to treat influenza because they specifically work by inhibiting bacterial cell wall production or protein synthesis and metabolism and have no effect on viruses. They can be used to treat secondary bacterial infections.
Factfile: Influenza

Vaccines
Antibodies that recognize the HA and NA surface proteins of the influenza virus can protect us from infection by stopping the virus reaching or binding to the host cell surface or by stopping new virions being released from the infected cell. This means that people will not be infected by the same strain of influenza after they recover from that flu. Giving a small dose of a crippled strain of influenza virus, or an injection of purified HA and NA protein as a vaccine, can stimulate the immune system to make antibodies to HA and NA to protect us from flu.

Flu epidemics and pandemics
The influenza virus genes are made of RNA and are more prone to mutations than genes made of DNA. The influenza viruses undergo constant genetic variation.

Antigenic drift
Influenza viruses are changing by antigenic drift all the time, constantly acquiring new mutations. Mutations in the genes coding for the proteins NA and HA result in minor changes to surface proteins at sites recognised by antibodies. If the HA antigen changes shape then the antibodies won’t be able to recognise it and bind to it as efficiently. The newly mutated virus can then bind to receptors on the host’s cell and infect it. This continual but gradual change of the sites recognised by antibodies is referred to as antigenic drift.

This is why it is possible for an individual to be infected more than once with influenza and why there is a global surveillance team that monitors the evolution of human influenza strains. Every year epidemic strains of influenza are slightly different from those that circulated the year before and the vaccine must be updated so that the antibodies it induces are a good match to the antigens of the strains that are circulating in the community.

Antigenic shift
Antigenic shift occurs in influenza A viruses only and is due to a human influenza virus acquiring new genes for the HA and NA protein from an influenza virus which infects animals. The new virus is so different from previous human and animal viruses that our existing antibodies are entirely unable to bind to it. This major change in HA and NA proteins, which allows the virus to side-step pre-existing immunity, is referred to as antigenic shift.

Wild birds get influenza infections all the time. Sometimes these avian viruses spread to chickens and cause outbreaks of ‘bird flu’ that can devastate poultry farms. Most bird flu viruses cannot infect humans. However, domesticated birds can transmit influenza to pigs. Pigs can transmit the virus to humans and vice versa. Reassortment of human and bird strains inside pigs can result in new strains of influenza A that will infect humans. That is why pigs can be referred to as a “mixing vessel”.

With the increase in global transport and urbanisation, epidemics caused by these new strains are likely to spread rapidly around the world. Theoretically these pandemics could be controlled by immunisation, but a new vaccine must be produced for each new strain of flu, which takes time, so vaccines may not be immediately available in the threat of an epidemic. The World Health Organization (WHO) has developed a ‘global influenza preparedness plan’ which advises countries on how to prepare for the possibility of an epidemic. This involves:
The unpredictability of pandemics!

The WHO is on constant lookout for the first signs of a pandemic. For some years there has been public concern that a strain of avian flu called influenza A H5N1 will mutate into a form that is easily transmitted between humans and cause a pandemic (H5 and N1 refer to the types of HA and NA proteins on the surface of this virus). The virus occurs in both wild and domesticated birds where it is transmitted in saliva, faeces and nasal secretions and has a high mortality rate. A small number of humans have contracted this strain of bird flu, mainly by close contact with poultry, and by October 2016 the WHO had confirmed 856 cases and 452 deaths worldwide. Currently there is very limited human-to-human transmission of these viruses and neither has yet created a highly transmissible pandemic strain.

In April 2009, scientists were surprised by the emergence of a novel influenza A H1N1 (2009) virus from Mexico. Popularly called ‘swine flu’, the strain contains a combination of genetic material from avian, swine and human flu viruses. It spread very rapidly around the world, causing 11,000 cases in 42 countries in the first 4 weeks. On 11 June 2009 the WHO declared the first global flu pandemic for 40 years. The pandemic was officially declared over in August 2010 although the strain continues to circulate.

The H1N1 (2009) strain was included in the 2010/2011 seasonal flu vaccine along with two other influenza strains. The H1N1 (2009) virus is expected to continue to circulate as a seasonal influenza strain for the foreseeable future and because of this, more people will develop immunity to this current version of the virus. However, the virus is also expected to change over time, meaning that immunity to this current strain may not protect against future strains of the virus. Global influenza surveillance will continue to track the evolution of H1N1 (2009).
Factfile: Influenza: A seasonal disease
First edition 2009; revised 2017

Acknowledgements
Thanks are due to Professor Wendy Barclay (Imperial College London) and Edward Hutchinson and Joanna Morrell (University of Glasgow) for their helpful comments on this text. Every care has been taken to ensure that the information is correct, but the author will be pleased to learn of any errors that have remained undetected.

Picture credits
Front/back cover, James Cavallini James/SPL*; p. 2, A. Dowsett, Public Health England/SPL; p. 3, CCI Archives/SPL; p. 4 top, Dr Steve Patterson/SPL; bottom, Voisin/Phanie/SPL; p. 5, Jan Van De Wel/Reporters/SPL; p. 6, James King-Homes/SPL; p. 7, Russell Kightley/SPL. *SPL, Science Photo Library

Copyright
Influenza: A seasonal disease is copyright. Microbiology Society asserts its moral right to be identified under Section 77 of the Design, Patents and Copyright Act, UK (1988).

Educational use: electronic or paper copies of the resources or individual pages from it may be made for classroom use and bona fide educational resources, provided that the copies are distributed free of charge or at the cost of reproduction and Microbiology Society is credited and identified as copyright holder.

© 2017 Microbiology Society

Microbiology Society
The Microbiology Society is a membership organisation for scientists who work in all areas of microbiology. It is the largest learned microbiological society in Europe with a worldwide membership based in universities, industry, hospitals, research institutes and schools. The Society publishes key academic journals, organises international scientific conferences and provides an international forum for communication among microbiologists and supports their professional development. The Society promotes the understanding of microbiology to a diverse range of stakeholders, including policymakers, students, teachers, journalists and the wider public, through a comprehensive framework of communication activities and resources.

The Society produces and distributes a wide range of resources including videos to support microbiology teaching in schools and colleges.

For more information, see www.microbiologyonline.org.uk or contact the Education Department, Microbiology Society, Charles Darwin House, 12 Roger Street, London WC1N 2JU, UK (education@microbiologysociety.org.uk).